CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice.

Mutations in the tumor suppressor p53 are detectable in over 50% of all human malignancies. Mutant p53 protein is incapable of transactivating its downstream target genes that are required for DNA repair and apoptosis. Chronic exposure to UVB induces p53 mutations and is carcinogenic in both murine and human skin. CP-31398, a styrylquinazoline compound, restores the tumor suppressor functions of mutant forms of p53 in tumor cells. However, its effectiveness in vivo remains unclear. Here, we demonstrate that CP-31398 blocked UVB-induced skin carcinogenesis and was associated with increases in p53, p21, and BclXs. CP-31398 downregulated Bcl2, proliferating nuclear cell antigen, and cyclin D1. Activation of caspase-3 and cleavage of poly (ADP-ribose) polymerase also occurred in both tumor and perilesional skin following treatment. CP-31398 induced the expression of p53-dependent target proteins, and this was followed by apoptosis in UVB-irradiated wild-type mice but not in their p53-deficient littermates. Similar effects were observed in human skin carcinoma A431 cells expressing mutant p53. In addition, CP-31398 induced mitochondrial translocation of p53, leading to changes in mitochondrial membrane permeability pore transition (MPT) and consequent cytochrome c release in these cells. Blocking MPT diminished p53 translocation and apoptosis. These studies indicate that reconstituting p53 tumor suppressor functions in vivo by small molecular weight compounds may block the pathogenesis and progression of skin cancer.

[1]  Gang Li,et al.  The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. , 2002, Experimental cell research.

[2]  Y. Ogawa,et al.  Reactive oxygen species-producing site in radiation and hydrogen peroxide-induced apoptosis of human peripheral T cells: Involvement of lysosomal membrane destabilization. , 2004, International journal of molecular medicine.

[3]  Ronen Marmorstein,et al.  Acridine derivatives activate p53 and induce tumor cell death through bax , 2005, Cancer biology & therapy.

[4]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[5]  W. El-Deiry,et al.  Targeting p53 by PTD-mediated transduction. , 2004, Trends in biotechnology.

[6]  K. Wiman,et al.  Small molecules that reactivate mutant p53. , 2003, European journal of cancer.

[7]  M. Hollstein,et al.  UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. , 2001, Cancer research.

[8]  Xin Wu,et al.  Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. , 2006, Experimental cell research.

[9]  W. El-Deiry,et al.  Cell cycle control as a basis for cancer drug development (Review). , 2000, International journal of oncology.

[10]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[11]  G. Halliday,et al.  Spectral and dose dependence of ultraviolet radiation-induced immunosuppression. , 2006, Frontiers in bioscience : a journal and virtual library.

[12]  U. Boelsterli,et al.  Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. , 2005, Free radical biology & medicine.

[13]  M. Stern,et al.  Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition. , 1995, The Journal of physiology.

[14]  C. V. van Kreijl,et al.  Dose-dependent effects of UVB-induced skin carcinogenesis in hairless p53 knockout mice. , 2005, Mutation research.

[15]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[16]  E. Dogliotti,et al.  Cell type and DNA damage specific response of human skin cells to environmental agents. , 2007, Mutation research.

[17]  W. El-Deiry,et al.  The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis , 2002, Cancer biology & therapy.

[18]  D. Green,et al.  Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. , 2003, Cancer cell.

[19]  Guillermina Lozano,et al.  Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation , 2003, Cell.

[20]  W. El-Deiry,et al.  Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding , 2003, Molecular and Cellular Biology.

[21]  D. Bickers,et al.  Novel Approaches to Chemoprevention of Skin Cancer , 2000, The Journal of dermatology.

[22]  Galina Selivanova,et al.  Characterization of the p53-rescue drug CP-31398 in vitro and in living cells , 2002, Oncogene.

[23]  M. Kastan.  Wild-Type p53: Tumors Can't Stand It , 2007, Cell.

[24]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[25]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[26]  M. Weller,et al.  CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death , 2003, Oncogene.

[27]  F. Gruijl,et al.  Mutations in cancer genes of UV-induced skin tumors of hairless mice. , 1999 .

[28]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[29]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[30]  Petr Pancoska,et al.  p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.

[31]  W. El-Deiry,et al.  Restoring p53-Dependent Tumor Suppression , 2003, Cancer biology & therapy.

[32]  D. Mitchell,et al.  THE BIOLOGY OF THE (6–4) PHOTOPRODUCT , 1989, Photochemistry and photobiology.

[33]  M. Reiss,et al.  Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. , 1992, Oncology research.

[34]  W. el-Deiry,et al.  Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling , 2001, Cell Death and Differentiation.

[35]  M. Pincus,et al.  Conformational and Molecular Basis for Induction of Apoptosis by a p53 C-terminal Peptide in Human Cancer Cells* , 1999, The Journal of Biological Chemistry.

[36]  O. Legrand,et al.  JC‐1, a sensitive probe for a simultaneous detection of P‐glycoprotein activity and apoptosis in leukemic cells , 2006, Cytometry. Part B, Clinical cytometry.

[37]  F. Gosselet,et al.  UVB-induced mutations in human key gatekeeper genes governing signalling pathways and consequences for skin tumourigenesis , 2003, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[38]  D. Lane,et al.  Small peptides activate the latent sequence-specific DNA binding function of p53 , 1995, Cell.

[39]  W. R. Bishop,et al.  Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody , 2005, Molecular Cancer Therapeutics.

[40]  D. Green,et al.  Dissecting p53-dependent apoptosis , 2006, Cell Death and Differentiation.

[41]  V. Rumjanek,et al.  Cyclosporin A does not protect the disruption of the inner mitochondrial membrane potential induced by potassium ionophores in intact K562 cells , 2006, Cell biology international.

[42]  T. Smith,et al.  J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. , 1991, Biochemistry.

[43]  E. Sausville,et al.  Contributions of human tumor xenografts to anticancer drug development. , 2006, Cancer research.

[44]  S. Korsmeyer,et al.  Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide , 2007 .

[45]  G. Li,et al.  Mutant p53 melanoma cell lines respond differently to CP‐31398‐induced apoptosis , 2005, The British journal of dermatology.

[46]  L. Möllgård,et al.  Effects of PRIMA‐1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion , 2004, British journal of haematology.

[47]  U. Moll,et al.  In Vivo Mitochondrial p53 Translocation Triggers a Rapid First Wave of Cell Death in Response to DNA Damage That Can Precede p53 Target Gene Activation , 2004, Molecular and Cellular Biology.

[48]  G. Giglia-Mari,et al.  TP53 mutations in human skin cancers , 2003, Human mutation.

[49]  N. Colburn,et al.  p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. , 2005, Cancer research.

[50]  Wafik S El-Deiry,et al.  Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Marx.  Recruiting the Cell's Own Guardian for Cancer Therapy , 2007, Science.

[52]  B. Starcher,et al.  A role for neutrophil elastase in solar elastosis. , 2007, Ciba Foundation symposium.

[53]  A. Chumakov,et al.  Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. , 1994, Oncogene.

[54]  M. Blagosklonny,et al.  P53: An ubiquitous target of anticancer drugs , 2002, International journal of cancer.

[55]  J. Cleaver,et al.  UV damage, DNA repair and skin carcinogenesis. , 2002, Frontiers in bioscience : a journal and virtual library.

[56]  W. El-Deiry,et al.  Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.

[57]  D. Alberts,et al.  Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. , 1994, Cancer letters.

[58]  G. Steele,et al.  Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Gautier,et al.  Stage-specific Alterations of Cyclin Expression During UVB-induced Murine Skin Tumor Development¶ , 2002, Photochemistry and photobiology.

[60]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.